Targeting BCL9/BCL9L enhances CD4(+) T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling.
Blocking specific Wnt pathway proteins activates anti-tumor immunity in preclinical models, opening a novel immunotherapy target for clinical investigation.
BCL9/BCL9L targeting activates a novel Wnt-STAT axis to boost CD4+ T cell-mediated antitumor immunity in preclinical cancer models. The mechanism expands actionable immunotherapy targets within the Wnt signaling pathway and warrants early-stage clinical investigation.
What the study was
- Study design
- Preclinical experimental study (in vitro and in vivo)
- Population
- Cancer cell lines and mouse tumor models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Acta pharmacologica Sinica
Why it surfaced
Novel BCL9/BCL9L-STAT1/4 immunotherapy axis; preclinical only; high novelty capped per non-human study rule.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.